La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Codexis a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Codexis..

Codexis (NASDAQ:CDXS) Azioni, Catena delle Opzioni

CODEXIS INC

Codexis

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Codexis Inc

WIIM

CDXS

Codexis shares are trading higher after the company announced it secured its first revenue deal for ECO Synthesis.

<ul>
<li>Represents first project to enter the ECO Synthesis&#x2122; Innovation Lab
<ul>
<li>Core enzymes for ECO Synthesis&#x2122; technology have transitioned from research into development and scale-up as the first step in securing the raw materials supply chain</li>
</ul>
</li>
</ul>

News

Codexis Secures First Revenue Deal For ECO Synthesis, Marks Milestone In Enzymatic siRNA Manufacturing

Codexis shares are trading lower after the company reported worse-than-expected Q4 financial results.

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) sees FY2025 sales of $64.000 million-$68.000 million vs $66.61 million analyst estimate.

Guidance

Codexis Sees FY2025 Sales $64.000M-$68.000M vs $66.61M Est

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.04) by 225 percent. This is a 30 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $21.46 million which missed the analyst consensus estimate of $27.41 million by 21.71 percent. This is a 19.20 percent decrease over sales of $26.56 million the same period last year.

Earnings

Earnings Misses

Codexis Q4 EPS $(0.13) Misses $(0.04) Estimate, Sales $21.46M Miss $27.41M Estimate

AAON

ABCL

ACEL

ACHC

ACHR

ACIC

ACIW

ADSK

AIRG

ALEX

ALHC

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARGX

ARLO

ARRY

ASTH

AUPH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CABO

CARS

CCOI

CLCO

CLOV

CMBT

CMLS

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CUBE

CVEO

CYTK

DAIO

DCGO

DELL

DUOL

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $11.0, with a high estimate of $11.00 and a low estimate of $11.00. This current average is unchanged from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1732287644_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Codexis among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Codexis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Codexis compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Codexis's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CDXS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Codexis analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Codexis: A Closer Look</h2>
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.
<h3>Financial Insights: Codexis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Codexis's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 38.33%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -160.84%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Codexis's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -30.61%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Codexis's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -14.73%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.57, Codexis adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Deep Dive Into Codexis Stock: Analyst Perspectives (4 Ratings)

Cantor Fitzgerald analyst Kristen Kluska reiterates Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) with a Overweight and maintains $11 price target.

Price Target

Reiteration

Cantor Fitzgerald Reiterates Overweight on Codexis, Maintains $11 Price Target

—Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset—
—Joint poster with Bachem demonstrates superiority of Company's double-stranded RNA ligases compared to wild-type enzymes—
—Management to host conference call today at 4:30 pm EST to discuss data—
REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced data from three presentations at the TIDES Europe annual meeting being held November 12-14, 2024, in Hamburg, Germany. The data demonstrate the Company's rapid advancement of its Enzyme Catalyzed Oligonucleotide (ECO) Synthesis&#x2122; manufacturing platform and establish Codexis' position at the forefront of enzymatic synthesis technology to enable to ongoing expansion of RNAi therapeutics.

Biotech

General

Codexis Unveils Pioneering Enzymatic Synthesis Data To Enable The Future Manufacturing Of RNAi Therapeutics; Management Hosted Conference Call Today At 4:30 pm EST To Discuss Data

Benchmark analyst Robert Wasserman reiterates Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) with a Hold.

Benchmark Reiterates Hold on Codexis

Codexis shares are trading higher after the company reported better-than-expected Q3 revenue results.

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) affirms FY2024 sales outlook from $56.00 million-64.00 million to $56.00 million-64.00 million.

Codexis Affirms FY2024 Product revenues $38M-$42M, R&D revenues $18M-$22M.

Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.23) by 26.09 percent. The company reported quarterly sales of $12.833 million which beat the analyst consensus estimate of $11.482 million by 11.77 percent. This is a 38.33 percent increase over sales of $9.277 million the same period last year.

Earnings Beats

Codexis Q3 2024 GAAP EPS $(0.29) Misses $(0.23) Estimate, Sales $12.833M Beat $11.482M Estimate

Management

Codexis Says Sriram Ryali Ceased To Serve As CFO And Principal Financial And Accounting Officer Effective As Of September 30, 2024

These funds are in addition to the&nbsp;$73.2 million&nbsp;in cash, cash equivalents and investments on hand as of June 30, 2024.&nbsp;In addition to the financing, the Company strengthened its management team through the appointments of Alison Moore&nbsp;to the newly created role of Chief Technology Officer and Georgia Erbez as Chief Financial Officer.

Codexis Reports Increase In Its Cash Reserves Through Capital Raises Totaling $31M Via Existing ATM Facility, Bringing Cash Runway Into 2027; Georgia Erbez Named As CFO

Codexis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>), a leading enzyme engineering company, today announced it has entered into a non-exclusive commercial and manufacturing license agreement with Alphazyme LLC, part of Maravai LifeSciences, for multiple enzymes in Codexis' life science enzyme portfolio. The agreement includes licenses for the HiFi DNA Polymerase, HiTemp Reverse Transcriptase, HiRev Isothermal Polymerase and other enzymes that were in development directed towards genomics and diagnostics applications prior to the Company's strategic shift announced in July 2023. Under the terms of the agreement, Codexis is eligible to receive sales-based royalties. &nbsp;
"As our manufacturing partner for the past three years—and with an existing genomics enzyme portfolio and sales force —Alphazyme is the natural choice to extend our commercial reach into this segment. We anticipate a smooth transition for our customers as there is no change in manufacturing supply and many of our customers are already familiar with the Alphazyme team," said Kevin Norrett, MBA, Chief Operating Officer at Codexis. "This transaction enables Codexis to maintain its focus on maximizing our near-term commercial opportunities and strategic priorities. This includes the growth of our Pharmaceutical Manufacturing business, increasing commercial adoption of the dsRNA ligase, and the build-out of our ECO Synthesis&#x2122; Innovation Lab to support manufacturing process development for our customers' preclinical siRNA assets. We remain on track to achieve key milestones for the ECO Synthesis&#x2122; platform this fiscal year, while delivering double-digit product revenue growth and maintaining a path to positive cash flow around the end of 2026."
Alphazyme is a premier partner for industrial-scale molecular biology enzymes. Alphazyme enthusiastically collaborates with manufacturers of nucleic acid synthesis and detection platforms to produce affordable, custom enzyme formulations of the highest quality that meet the specifications of the rapidly expanding markets for custom DNA and RNA molecules, genomic medicines and genetic testing.&nbsp;"The Codexis and Alphazyme relationship has been strong for many years. We are excited to take on Codexis' portfolio of high-performing life science and diagnostic enzymes and be a part of their continued success," said Chad Decker, Vice President and General Manager of Alphazyme. This new collaboration will leverage the experience and industry knowledge of the Alphazyme team to enhance the commercialization of Codexis' portfolio of life science and diagnostic enzymes.
This license agreement marks another transaction in which Codexis is executing on its strategy to divest the Company's non-core assets following its strategic shift to focus on the growth of its Pharmaceutical Manufacturing business and Enzyme Catalyzed Oligonucleotide (ECO) Synthesis&#x2122; manufacturing platform.

MRVI

Codexis Licenses Key Enzymes to Alphazyme, Sharpening Focus on Pharmaceutical Growth

Press Releases

Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th

Codexis Announces New Employment Inducement Grants

Codexis to Participate in TD Cowen 45th Annual Health Care Conference

Codexis Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Codexis Announces First Revenue-Generating Contract for ECO Synthesis™ Manufacturing Services

Codexis Appoints Cynthia Collins to Board of Directors

Codexis Announces Byron Dorgan to Retire from Board of Directors

Codexis to Report First Quarter 2025 Financial Results on May 14

Health Care

Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting

Comments

Codexis

Codexis (CDXS) Opzioni

Codexis (NASDAQ:CDXS) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO